SETD2 and renal cell carcinoma: Comparison of the molecular landscape between our own RCC PDX panel and TCGA data (TCGA Research Network: http://cancergenome.nih.gov/) of representative patient cohorts revealed that the PDX covered most of the described genetic mutations of the malignancy; relevant driver mutations including VHL, BAP1, PBRM1 and SETD2 were represented in our PDX panel.